Chemotherapy for endocrine-therapy-refractory prostate cancer

Area of Science:

• Oncology
• Medical Oncology
• Prostate Cancer Research

Background:

• Endocrine-therapy-refractory prostate cancer presents a significant treatment challenge.
• Chemotherapy is a key treatment modality for advanced prostate cancer.
• Identifying effective chemotherapy regimens is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of various chemotherapy regimens in patients with endocrine-therapy-refractory prostate cancer.
• To compare the survival outcomes associated with different single-agent and combination chemotherapy regimens.
• To investigate the correlation between tumor proliferation rate and chemotherapy response.

Main Methods:

• A retrospective analysis of 64 patients with endocrine-therapy-refractory prostate cancer receiving chemotherapy at first relapse.
• Chemotherapy regimens included single agents (cisplatin, ifosfamide) and combinations (VIP, CAP, IAP, EAP).
• Patient outcomes were assessed based on cause-specific survival, PSA/PAP levels, and PSA doubling time.

Main Results:

• No significant difference in cause-specific survival was observed between combination regimens (CAP, IAP, EAP) and single agents plus VIP when adjusted for time to chemotherapy.
• Patients responding to chemotherapy (complete response, partial response, no change) demonstrated longer survival than those with progressive disease.
• Pre-chemotherapy PSA doubling time correlated with chemotherapy response, indicating slower-growing tumors responded better.

Conclusions:

• No single chemotherapy regimen demonstrated superior efficacy in endocrine-therapy-refractory prostate cancer.
• Tumor proliferation rate, as indicated by PSA doubling time, is a significant factor influencing chemotherapy response.
• Slower-growing prostate tumors may benefit more from chemotherapy compared to rapidly proliferating ones.